Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationDepreciation & Amortization (IS)Long-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Savara (SVRA) Other Gross PP&E Adjustments (2011 - 2025)

Savara (SVRA) reported Other Gross PP&E Adjustments of -$2.0 million for Q4 2025, down 56.08% year-over-year from -$4.6 million in Q4 2024, and down 56.08% on a QoQ basis from -$1.3 million in Q4 2024.

Savara (SVRA) has 15 years of Other Gross PP&E Adjustments data on file, last reported at -$2.0 million in Q4 2025.

  • Quarterly Other Gross PP&E Adjustments fell 56.08% year-over-year to -$2.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$2.0 million (down 56.08% YoY) and the FY2025 annual result came in at -$2.0 million, down 56.08% from the prior year.
  • Other Gross PP&E Adjustments fell to -$2.0 million in Q4 2025 per SVRA's latest filing, from -$1.3 million in the prior quarter.
  • Across five years, Other Gross PP&E Adjustments topped out at $2.3 million in Q4 2023 and bottomed at -$2.0 million in Q4 2025.
  • The 5-year median for Other Gross PP&E Adjustments is $2.0 million (2022), against an average of $620400.0.
  • The widest annual swing landed in 2023, when Other Gross PP&E Adjustments advanced 15.6%; it then sank 156.57% in 2024.
  • Tracing SVRA's Other Gross PP&E Adjustments over 5 years: stood at $2.2 million in 2021, then slipped by 8.27% to $2.0 million in 2022, then increased by 15.6% to $2.3 million in 2023, then slumped by 156.57% to -$1.3 million in 2024, then plunged by 56.08% to -$2.0 million in 2025.
  • Per Business Quant, the three latest SVRA Other Gross PP&E Adjustments figures stand at -$2.0 million (Q4 2025), -$1.3 million (Q4 2024), and $2.3 million (Q4 2023).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Other Gross PP&E Adjustments (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -83,048.00
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -60,691.22
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -285.20 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -892,000.00
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -1.69 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -189.30 Mn
10 Savara 1.30 Bn 1.30 Bn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 -2.02 Mn
Dec 31, 2025 -2.02 Mn
Dec 31, 2024 -1.29 Mn
Dec 31, 2024 -1.29 Mn
Dec 31, 2023 2.28 Mn
Dec 31, 2023 2.28 Mn
Dec 31, 2022 1.97 Mn
Dec 31, 2022 1.97 Mn
Dec 31, 2021 2.15 Mn
Dec 31, 2021 2.15 Mn
Dec 31, 2020 2.13 Mn
Dec 31, 2020 2.13 Mn
Dec 31, 2019 2.03 Mn
Dec 31, 2019 2.03 Mn
Dec 31, 2018 1.89 Mn
Dec 31, 2018 1.89 Mn
Dec 31, 2017 1.78 Mn
Dec 31, 2017 1.78 Mn
Dec 31, 2016 -1.73 Mn
Dec 31, 2016 -1.73 Mn
Dec 31, 2015 -2.05 Mn
Dec 31, 2015 -2.05 Mn
Dec 31, 2014 -1.71 Mn
Dec 31, 2014 -1.71 Mn
Dec 31, 2013 -1.38 Mn
Dec 31, 2013 -1.38 Mn
Dec 31, 2012 -843,654.00
Dec 31, 2012 -843,654.00
Dec 31, 2011 738,652.00
Dec 31, 2011 738,652.00